| Date | Title | | | 11/25/08 | Inspire Announces Webcast of Presentation at Piper Jaffray Conference| DURHAM, N.C., Nov 25, 2008 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Christy L. Shaffer, Ph.D., President and CEO, will present at the Piper
Jaffray 20th Annual Health Care Conference Tuesday, December 2, 2008 at
9:30 am ET in New York City.
Also in conjunction with the conference, Benjamin R. Yerxa, Ph.D.,
Executive Vice President and Chief, Research and Development, will
participate on a cystic fibrosis panel W... |
|  | | 10/31/08 | Inspire Reports Third Quarter 2008 Financial Results| Q3 2008 Revenue Increased by 63% over Q3 2007
DURHAM, N.C.--(BUSINESS WIRE)--Oct. 31, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the third quarter ended September 30, 2008, reporting a net loss
of $9.6 million, or ($0.17) per share.
Total revenue for the third quarter of 2008 was $20.0 million, as
compared to $12.2 million for the third quarter of 2007. Revenue from
AzaSite(R) (azithromycin ophthalmic solution) 1%, a bacterial
con... |
| | | 10/24/08 | Inspire Announces New Data from Denufosol Phase 3 Program at North American Cystic Fibrosis Conference|
-TIGER-1 Open-Label Extension Completed-
-Open-Label Extension Suggests Progressive Improvement in FEV(1)-
DURHAM, N.C.--(BUSINESS WIRE)--Oct. 24, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the presentation
of additional data from TIGER-1, the Company's first Phase 3 trial
with denufosol tetrasodium for the treatment of cystic fibrosis, at
the 22nd Annual North American Cystic Fibrosis Conference (NACFC) in
Orlando, FL on October 23 - 25, 2008.
... |
| | | 10/17/08 | Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 17, 2008--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that
it plans to report third quarter 2008 financial results on Friday,
October 31, 2008 before the market opens. Inspire's President and CEO,
Christy L. Shaffer, Ph.D., and Executive Vice President and CFO,
Thomas R. Staab, II, will host a conference call and live webcast on
Friday, October 31, 2008 at 10:00 a.m. ET.
To access the conference call, U.S. participants may call
8... |
| | | 10/15/08 | Inspire Announces Issuance of Patent for Elestat(R)| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 15, 2008--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
the U.S. Patent and Trademark Office has issued a method of treatment
patent related to Elestat(R) (epinastine HCl ophthalmic solution)
0.05% for allergic conjunctivitis. This patent, U.S. Patent No.
7,429,602, entitled "Treating Conjunctivitis by Administering an
Epinastine Solution to the Conjunctiva," was issued to Boehringer
Ingelheim International GmbH, the developer of ... |
| | | 10/09/08 | Inspire Initiates Phase 1 Trial of INS117548 For Glaucoma| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 9, 2008--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced that it has
initiated a Phase 1 clinical trial with INS117548 Ophthalmic Solution
for the treatment of glaucoma.
The placebo-controlled, dose-escalating trial is designed to
evaluate the safety, tolerability and intraocular pressure
(IOP)-lowering effects of INS117548 in approximately 60 subjects with
early stage glaucoma or ocular hypertension. INS117548 is a Rho kinase
inhibitor de... |
| | | 09/23/08 | Inspire Initiates Special Protocol Assessment Process for Prolacria(TM) Trial for Dry Eye| DURHAM, N.C.--(BUSINESS WIRE)--Sept. 23, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has submitted
a clinical protocol and request for Special Protocol Assessment (SPA)
to the U.S. Food and Drug Administration (FDA) for a pivotal Phase 3
environmental trial with Prolacria(TM) (diquafosol tetrasodium
ophthalmic solution) for the treatment of dry eye disease.
The protocol is based on information from a detailed analysis of
the overall Prolacria clinical tri... |
| | | 09/18/08 | Inspire Announces Webcast of Presentation at UBS Conference| DURHAM, N.C.--(BUSINESS WIRE)--Sept. 18, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R.
Staab, II, CFO and Treasurer, will present at the UBS Global Life
Sciences Conference on Thursday, September 25, 2008 at 1:00 pm ET in
New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
time followi... |
| | | 09/11/08 | Inspire Announces Plans for Clinical Testing of New Compound INS117548 for the Treatment of Glaucoma| DURHAM, N.C., Sep 11, 2008 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the
standard 30-day review period by the U.S. Food and Drug Administration
(FDA) relating to Inspire's Investigational
New Drug Application (IND) for INS117548 Ophthalmic Solution for the
treatment of glaucoma has concluded and clinical testing can proceed.
Inspire is currently targeting the initiation of a Phase 1 clinical
trial by the end of 2... |
| | | 08/12/08 | Inspire Announces Webcast of Presentation at Noble Financial Conference| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 12, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R.
Staab, II, CFO and Treasurer, will present at the Noble Financial
M.A.D. Max Equity Conference on Monday, August 18, 2008 at 1:00 pm PST
at the Loews Lake Las Vegas Resort, Nevada.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this li... |
| | | 08/11/08 | Inspire Reports Second Quarter 2008 Financial Results| - Q2 2008 Revenue Increased by 43% over Q2 2007 -
DURHAM, N.C.--(BUSINESS WIRE)--Aug. 11, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today financial results
for the second quarter ended June 30, 2008, reporting a net loss of
$6.4 million, or ($0.11) per share.
Total revenue for the second quarter of 2008 was $22.0 million, as
compared to $15.4 million for the second quarter of 2007. Revenue from
AzaSite(R) (azithromycin ophthalmic solution) 1%, a bacterial
co... |
| | | 08/06/08 | Inspire Announces Peer-Reviewed Publications Related to Denufosol for Cystic Fibrosis| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 6, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today publication of
two papers related to the denufosol for cystic fibrosis development
program in peer-reviewed journals.
The first paper, "Denufosol: A Review of Studies with Inhaled P2Y2
Agonists that led to Phase 3" (D. Kellerman, A. Rossi Mospan, J.
Engels, A. Schaberg, J. Gorden, L. Smiley), was published in Pulmonary
Pharmacology & Therapeutics August 2008, Volume 21, Issue ... |
| | | 07/29/08 | Inspire Provides Update on Cystic Fibrosis Clinical Program| - Optimization of TIGER-2 Trial Design -
DURHAM, N.C.--(BUSINESS WIRE)--July 29, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced modifications to the
clinical protocol for TIGER-2, the Company's ongoing second Phase 3
trial with denufosol tetrasodium for the treatment of cystic fibrosis
(CF).
"The availability of the extensive data set from the positive
TIGER-1 trial provides an excellent opportunity to optimize the
TIGER-2 trial design," stated Christy L. Shaffe... |
| | | 07/28/08 | Inspire Announces Date for Conference Call to Discuss Second Quarter 2008 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--July 28, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to
report second quarter 2008 financial results on Monday, August 11,
2008 before the market opens. Inspire's President and CEO, Christy L.
Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host
a conference call and live webcast on Monday, August 11, 2008 at 10:00
a.m. ET.
To access the conference call, U.S. participants may call (877)
648-7970 ... |
| | | 07/01/08 | Inspire Announces Webcast of Presentation at Collins Stewart Growth Conference| DURHAM, N.C.--(BUSINESS WIRE)--July 1, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO of Inspire, will present at the
Collins Stewart Fourth Annual Growth Conference on July 8, 2008 at
10:30 am ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
... |
| | | 06/25/08 | Inspire Named One of the ``Best Places to Work'' in 2008 by The Scientist Magazine| - Company Also Receives Two Employee Wellness Awards -
DURHAM, N.C.--(BUSINESS WIRE)--June 25, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) ranked second overall in the
"Best Places to Work in Industry" annual survey conducted by The
Scientist magazine, published in June 2008. This is the third year
Inspire received the award and the second year in a row the Company
ranked in the top five. The survey included responses from more than
200 U.S. and internationally based comp... |
| | | 06/18/08 | Inspire Announces Webcast of Presentation at Piper Jaffray Europe Conference| DURHAM, N.C.--(BUSINESS WIRE)--June 18, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO of Inspire, will present at the
Piper Jaffray Europe Conference on Wednesday, June 25, 2008 at 10:40
am GMT in London, England.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
... |
| | | 06/06/08 | Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis| Conference Call Scheduled for 9:00 AM ET on June 6, 2008 Detailed Results to Be Presented at North American Cystic Fibrosis Conference in October 2008DURHAM, N.C., Jun 06, 2008 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today
top-line results from the 352-patient, double-blind, 24-week
placebo-controlled portion of its Phase 3 trial (TIGER-1) with
denufosol tetrasodium inhalation solution for the treatment of cystic
fibrosis (CF).
The trial demonstrated statis... |
| | | 05/16/08 | Inspire Receives Milestone Payment for Completion of Phase 3 Testing in Japan for Dry Eye Program| DURHAM, N.C.--(BUSINESS WIRE)--May 16, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the receipt of a
$1.25 million milestone payment from its Asian dry eye partner, Santen
Pharmaceutical Co., Ltd., related to the completion of Santen's Phase
3 testing of diquafosol tetrasodium, referred to as DE-089, for the
treatment of dry eye. Santen has announced that it expects to file an
application by the end of June 2008 for marketing approval in Japan.
Inspire and ... |
| | | 05/08/08 | Inspire Reports First Quarter 2008 Financial Results| - Q1 2008 Revenue Increased by 35% over Q1 2007 -
DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the first quarter ended March 31, 2008, reporting a net loss of
$25.9 million, or ($0.46) per share.
Total revenue for the first quarter of 2008 was $9.7 million, as
compared to $7.2 million for the first quarter of 2007, reflecting an
increase of 35%. Revenue from AzaSite(R) (azithromycin ophthalmic
s... |
| | | 04/25/08 | Inspire Announces Poster Presentations at 2008 Association for Research in Vision and Ophthalmology Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--April 25, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
scientists and collaborators will present information in four poster
presentations at the 2008 Association for Research in Vision and
Ophthalmology (ARVO) annual meeting April 27 - May 1, 2008 in Ft.
Lauderdale, Florida.
One poster presentation, "Evaluation of MMP2/9 Modulation by
Azithromycin and DuraSite on Corneal Epithelial Cells in vitro," is
related to Az... |
| | | 04/24/08 | Inspire Announces Webcasts of Presentations at Morgan Stanley and Deutsche Bank Healthcare Conferences| DURHAM, N.C.--(BUSINESS WIRE)--April 24, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R.
Staab, II, CFO and Treasurer, and Benjamin R. Yerxa, Ph.D., Chief
Scientific Officer and Executive Vice President, Strategic Operations,
will present at the Morgan Stanley Global Healthcare Unplugged
Conference on Thursday, May 1, 2008 at 11:20 am ET in Key Biscayne,
Florida. The Company also announced that Christy L. Shaffer, Ph.D.,
President and CEO, will presen... |
| | | 04/24/08 | Inspire Announces Date for Conference Call to Discuss First Quarter 2008 Financial Results| DURHAM, N.C., Apr 24, 2008 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
it plans to report first quarter 2008 financial results on Thursday,
May 8, 2008 before the market opens. Inspire's President and CEO,
Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II,
will host a conference call and live webcast on Thursday, May 8, 2008
at 10:00 a.m. ET.
To access the conference call, U.S. participants may call (877)
648-7970 and internatio... |
| | | 04/23/08 | Inspire to Discontinue Development of Epinastine Nasal Spray| DURHAM, N.C.--(BUSINESS WIRE)--April 23, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that its Phase 3
trial with epinastine nasal spray for the treatment of seasonal
allergic rhinitis (SAR) did not meet its primary endpoint.
"Our analysis of the overall data in this program and the current
competitive environment in allergic rhinitis indicate that epinastine
nasal spray does not show potential to meet our desired product
profile in the United States," stat... |
| | | 04/04/08 | Inspire Announces Poster Presentation at American Society of Cataract and Refractive Surgery Annual Symposium| DURHAM, N.C.--(BUSINESS WIRE)--April 4, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
scientists and collaborators will present information in a poster
presentation at the American Society of Cataract and Refractive
Surgery 2008 Symposium on April 4-9, 2008 in Chicago, IL.
The poster, "Comparison of AzaSite(R) and Azithromycin 1% for
Bacterial Conjunctivitis" (C. Crean, J. Vittitow, R. Zink, L.
Richards, R. Verhoeven, K. Powell and R.K. Brazzell),... |
| | | 03/14/08 | Inspire Announces Poster Presentations at 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--March 14, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
scientists and collaborators will present information in two poster
presentations at the 2008 American Academy of Allergy, Asthma &
Immunology (AAAAI) Annual Meeting being held March 14 - 18, 2008 in
Philadelphia.
The poster entitled "Pharmacokinetic Model of Epinastine, an H1
Antagonist, after Nasal Administration" (C. Crean, P. Ratner, M.
Widmann, A. Sc... |
| | | 03/11/08 | Inspire Announces Webcast of Presentation at Cowen and Company Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--March 11, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R.
Staab, II, CFO and Treasurer, and Ward M. Peterson, Ph.D., Vice
President, Research and Preclinical Development, will present at the
Cowen and Company 28th Annual Health Care Conference, March 18, 2008
at 11:00 am ET in Boston.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
p... |
| | | 03/10/08 | Inspire Director William R. Ringo to Resign Board Position| DURHAM, N.C.--(BUSINESS WIRE)--March 10, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that William R.
Ringo, Jr. will resign from the Board of Directors of Inspire
Pharmaceuticals, Inc., at the Company's annual meeting scheduled for
June 10, 2008. Mr. Ringo has accepted a position as Senior Vice
President of Strategy and Business Development at Pfizer Inc.
"Since joining the Inspire Board in 2003, Bill has been a great
contributor," stated Kenneth B. Lee, Jr.... |
| | | 02/27/08 | Inspire Announces Webcast of Presentation at Susquehanna Healthcare Conference| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 27, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R.
Staab, II, CFO and Treasurer, and Donald J. Kellerman, Pharm.D, Senior
Vice President of Development, will present at Susquehanna Financial
Group's Second Annual SIGnificant Options in Healthcare Conference on
Wednesday, March 5, 2008 at 9:30 am ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com... |
| | | 02/26/08 | Inspire Reports Fourth Quarter and Full Year 2007 Financial Results|
- Fourth Quarter Revenue Increased 64% Over 2006 -
- Full Year Revenue Increased 31% Over 2006 -
DURHAM, N.C.--(BUSINESS WIRE)--Feb. 26, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the fourth quarter and year ended December 31, 2007, reporting a
net loss of $18.1 million for the fourth quarter and a net loss of
$63.7 million for the full year. In the fourth quarter, the Company
recorded a non-cash dividend of $8.3 mil... |
| | | 02/13/08 | Inspire Initiates Second Phase 3 Cystic Fibrosis Trial| TIGER-2 Targeting Enrollment of 350 Patients with Mild Cystic Fibrosis Lung DiseaseDURHAM, N.C., Feb 13, 2008 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the
initiation of TIGER-2, its second pivotal Phase 3 clinical trial with
denufosol tetrasodium inhalation solution for the treatment of cystic
fibrosis (CF).
TIGER-2 (Transport of Ions to Generate Epithelial Rehydration) is
a 24-week, double-blind, placebo-controlled, randomized study
comparing 60 mg o... |
| | | 02/12/08 | Inspire Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 12, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to
report fourth quarter and full year 2007 financial results on Tuesday,
February 26, 2008 before the market opens. Inspire's President and
CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R.
Staab, II, will host a conference call and live webcast on Tuesday,
February 26, 2008 at 10:00 a.m. ET.
To access the conference call, U.S. participants may c... |
| | | 02/06/08 | Inspire Announces Webcasts of Presentations at BIO CEO and Roth Growth Stock Conferences| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 6, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
senior management will present at the 10th Annual BIO CEO & Investor
Conference on Wednesday, February 13, 2008 at 11:00 am ET in New York
City and at the Roth 20th Annual Growth Stock Conference on Wednesday,
February 20, 2008 at 12:30 pm PT (3:30 pm ET) in Dana Point, CA.
The webcasts of the presentations will be available on Inspire's
web site at www.inspirepha... |
| | | 01/18/08 | Inspire Provides 2008 Financial Guidance| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 18, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today revenue and
expense guidance for the full year of 2008.
Inspire expects to record aggregate revenue in the range of
$62-$76 million and expects operating expenses to be in the range of
$109-$129 million in 2008. Based on current operating plans, the
Company expects its cash and investments would provide liquidity
through 2009. The revenue range is based on projected sales fro... |
| | | 01/14/08 | Inspire Announces Its Termination of Bilastine Licensing Agreement| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 14, 2008--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has
exercised its option to terminate the licensing agreement with FAES
Farma, S.A. for the U.S. and Canadian development and
commercialization of oral bilastine for the treatment of allergic
rhinitis. Inspire is terminating the agreement in its entirety, and as
a result, Inspire is no longer responsible for the development and
commercialization of the oral or ocular form... |
| |
|
